Update re AbC-19TM Rapid Test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today’s update from Abingdon Health plc (AIM: ABDX) (“Abingdon Health”) regarding the AbC-19TM Rapid Test, confirming their expectations for future supply arrangements with the Department of Health and Social Care, the ongoing efforts to obtain regulatory approvals in a total of 27 geographies, and the ongoing work to build data the set(s) around the use-case for the AbC-19TM Rapid Test alongside vaccines.
In addition, Omega will today announce the laun ch of its COVID-19 antibody lab-based testing service in Littleport, Cambridgeshire (see separate RNS Reach for details), using the Mologic ELISA1 antibody test. This service will be offered to commercial occupational health partners, clinics and health care professionals in the UK.
Colin King, CEO of Omega Diagnostics, said: “We welcome the update from Abingdon Health this morning and look forward to being able to update investors on the potential to open up significant commercial opportunities outside of the UK in due course.”
Launch of COVID-19 antibody laboratory-based testing service
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has launched the Mologic ELISA1 antibody test for COVID-19 through its in-house testing laboratory service in Littleport, Cambridgeshire .
This follows the successful CE marking of the capillary blood sample collection pack which is sent to healthcare professionals who then send the patient’s sample back to the Company’s laboratory, where the test is then run. Test results are then sent back to each healthcare professional who informs the patient of their result and provides advice as necessary.
The Company expects to offer this testing service to selected commercial occupational health partners, clinics and health care professionals in the UK.
Colin King, CEO of Omega commented: “We are pleased that we have delivered on our committed timeline for the launch of the lab testing service. This highlights our ability to react to changing market needs and utilises the skills and expertise of our long-established service Laboratory.”
1 ELISA (Enzyme Linked Immuno-Sorbent Assay) tests are one of the most tested and proven laboratory technologies used by the global diagnostic industry and remain the principal reference point from which rapid diagnostics are coordinated, especially serological tests, including tests for COVID-19.
